Mitomycin

• 

  Subject Areas on Research

  • A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. 
  • A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. 
  • A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. 
  • Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. 
  • Aqueous shunt devices compared with trabeculectomy with Mitomycin-C for children in the first two years of life. 
  • Aqueous shunt devices compared with trabeculectomy with mitomycin-C for children in the first two years of life. 
  • Arabidopsis BRCA2 and RAD51 proteins are specifically involved in defense gene transcription during plant immune responses. 
  • Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. 
  • Atypical Fibroxanthoma of the Bulbar Conjunctiva. 
  • Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. 
  • Can topical mitomycin prevent laryngotracheal stenosis? 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. 
  • Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. 
  • Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. 
  • Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. 
  • Current management of anal canal cancer. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. 
  • DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. 
  • Echographic diagnosis of scleral fold in hypotony. 
  • Effects of donor splenocytes treated with mitomycin C on rat hepatic, cardiac, and intestinal allografts. 
  • Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. 
  • Evolution and Management of Treatment-Related Toxicity in Anal Cancer. 
  • Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. 
  • Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy. 
  • Genetic composition of the Bacillus subtilis SOS system. 
  • Histology of conjunctival vascular endothelium after filtering surgery with mitomycin C in rabbits. 
  • Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer? 
  • Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. 
  • Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 
  • Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer. 
  • Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). 
  • Inhibition of cell proliferation by mitomycin C incorporated into P(HEMA) hydrogels. 
  • Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. 
  • Intensity-modulated radiation therapy for anal cancer. 
  • Interaction of FANCD2 and NBS1 in the DNA damage response. 
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. 
  • Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. 
  • Laser suture lysis after mitomycin C trabeculectomy. 
  • Lisch nodules after trabeculectomy. 
  • Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. 
  • Management of suprachoroidal hemorrhage. 
  • Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. 
  • Migrating keratinocytes express urokinase-type plasminogen activator. 
  • Mitomycin C-augumented trabeculectomy with postoperative wound modulation in pediatric glaucoma. 
  • Mitomycin-C concentration in human aqueous humour following trabeculectomy. 
  • Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. 
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC. 
  • RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. 
  • Repair of mitomycin C cross-linked DNA in mammalian cells measured by a host cell reactivation assay. 
  • Results of trabeculectomy with 0.3 mg/ml mitomycin C titrating exposure times based on risk factors for failure. 
  • Retinal vein occlusion after trabeculectomy with mitomycin C. 
  • Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. 
  • Suppression of hepatic allograft rejection in the rat by mitomycin C-treated donor splenocytes: analysis of the immune status. 
  • Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? 
  • The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. 
  • Three-dimensional high-speed optical coherence tomography for diagnosis of hypotony maculopathy after glaucoma filtration surgery. 
  • Three-year follow-up of the tube versus trabeculectomy study. 
  • Time-dose considerations in the treatment of anal cancer. 
  • Trabeculectomy in pseudophakic patients: postoperative 5-fluorouracil versus intraoperative mitomycin C antiproliferative therapy. 
  • Trabeculectomy with mitomycin-C in pediatric glaucomas. 
  • Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. 
  • Treatment of superficial carcinoma of the bladder. 
  • Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. 
  • Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. 
  • Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. 
  • US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Variable allograft responses to pretreatment with donor splenocytes treated with mitomycin C in the rat. 
• 

  Keywords of People

  • Preminger, Glenn Michael, James F. Glenn, M.D. Professor of Urology, Surgery